Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin Irritation and Sensitization of d-ATS Patch in Healthy Adults
NCT04094025Phase 1Completed
- Sponsor
- Noven Therapeutics, LLC
- Start
- Dec 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of dextroamphetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Noven Therapeutics, LLC. Primary endpoints: Sensitization at 21 days and Irritation at 21 days. Started Dec 2019; status: completed.
02
Drugs
dextroamphetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT04094025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094025.